Clinical trials: Fatty Liver, Alcoholic
Fatty Liver, Nonalcoholic, NAFLD
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
- Conditions
- Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03656744
- Testing
- HTD1801
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
Insulin Resistance, Prediabetic State
Human Models of Selective Insulin Resistance: Alpelisib, Part I
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes.
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT06354088
- Testing
- Alpelisib 300 mg, [1-13C] sodium acetate, [6,6-2H2] D-glucose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Columbia University
Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease
Detecting Liver Fibrosis in Patients At-risk
The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register.
- Conditions
- Fatty Liver, NAFLD - Non-Alcoholic Fatty Liver Disease, Nash, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
- Trial name
- STELIR (NCT07775638)
- Testing
- Routine study procedure
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Liver Biomarkers, Lipid Profile
Improvement in Hepatic Function Through Sumac (Rhus Coriaria L.) Supplement Along With a Calorie-restricted Diet for the Management of Grade-I Obese Non-alcoholic Fatty Liver Disease Patients
This randomized controlled trial aims to evaluate the effects of Rhus coriaria L. (Sumac) supplementation combined with a calorie-restricted diet on hepatic function and metabolic health in grade-I obese patients with…
- Conditions
- Liver Biomarkers, Lipid Profile, Glucose, Insulin
- Trial name
- NCT07768657
- Testing
- T1 SUMAC SUPPLEMENT, T2 SUMAC SUPPLEMENT
- Where
- Pakistan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Non Alcoholic Fatty Liver Disease
Effects of Turkish Coffee and Green Tea in Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a common liver condition associated with metabolic disorders and lifestyle factors.
- Trial name
- NCT07768956
- Testing
- green tea, Turkish Coffee, mediterranean diet
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Okan University
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver.
- Trial name
- NCT04550481
- Testing
- Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Diabete Type 2, Non Alcoholic Fatty Liver
Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple…
- Trial name
- AS-NAFLD (NCT07338331)
- Testing
- Aspirin, Dapagliflozin (10Mg Tab) along with standard medical therapy, Metformin 1000 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Galala University
NAFLD
NASH AMPK Exercise Dosing (AMPED) Trial
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH.
- Trial name
- AMPED (NCT04987879)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
- Trial name
- CENTRICITY (NCT05623189)
- Testing
- HTD1801
- Where
- 45 sites in United States, Hong Kong and 1 more
- Volunteers
- 218 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver
Digital Therapy for Fatty Liver Disease
This study is a randomised controlled trial of the clinical application of the Fatty Liver Data Analysis and Intervention System (FLDAS) to compare the effectiveness of traditional lifestyle interventions in patients with fatty…
- Trial name
- DTFLD (NCT07007741)
- Testing
- Software Group
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
NASH - Nonalcoholic Steatohepatitis
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited.
- Trial name
- NCT04833140
- Testing
- Estradiol patch
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Obesity, Nonalcoholic Fatty Liver
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
- Trial name
- ATM (NCT06335771)
- Testing
- Dietary consultation weight loss intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Obesity, Non-Alcoholic Fatty Liver Disease
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
- Trial name
- ATM (NCT06571474)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD
- Trial name
- NCT06176079
- Testing
- Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Michael Ohliger, MD PhD
Liver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
- Trial name
- STARLIGHT (NCT06613698)
- Testing
- GSK4532990
- Where
- 140 sites in United States, Argentina and 16 more
- Volunteers
- 393 people
- Sponsor
- GlaxoSmithKline